Global Monoclonal Antibody Based Products

Monoclonal Antibody Based Products Comprehensive Study by Type (Murine, Chimeric, Humanized, Human), Application (Therapeutics, Diagnostics), Diseases Type (Non-communicable Diseases, Infectious Diseases), End-User (Pharmaceutical Companies, Global Health Agencies, Public Sector Entities, Philanthropic Organisations, Others) Players and Region - Global Market Outlook to 2030

Monoclonal Antibody Based Products Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Monoclonal Antibody Based Products
Monoclonal antibody-based products are one of the most powerful tools in modern medicine. Most licensed monoclonal antibodies are for non-communicable diseases, including cancer and autoimmune diseases. It is a large and growing segment of the pharmaceutical market and is the largest class of biologic products in development. Health systems strengthen and improve the capabilities to diagnose and treat disease in developing countries.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


Global Monoclonal Antibody Based Products is a fragmented market due to the presence of various players. The players are focusing on investing more in Launching New Products. These will enhance their market presence. The companies are also planning strategic activities like partnerships, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Merck Group (Germany), Genentech/Roche (United States), AbbVie (United States), Amgen/Pfizer (United States), MedImmune (United States), Zydus Lifesciences (India), Serum Institute (India), BD Biosciences (United States), Amgen (United States) and Biotest (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Dendreon (United States) and Biogen (United States).

Segmentation Overview
AMA Research has segmented the market of Global Monoclonal Antibody Based Products market by Type (Murine, Chimeric, Humanized and Human), Application (Therapeutics and Diagnostics) and Region.



On the basis of geography, the market of Monoclonal Antibody Based Products has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diseases Type, the sub-segment i.e. Non-communicable Diseases will boost the Monoclonal Antibody Based Products market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-User, the sub-segment i.e. Pharmaceutical Companies will boost the Monoclonal Antibody Based Products market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Raising Awareness of the Clinical, Public Health, and Economic Value

Market Growth Drivers:
Increasingly Large Proportion of Pharmaceutical Company Pipelines and Rising Awareness about Monoclonal Antibodies

Challenges:
Limitations on the Monoclonal Antibody-Based Products

Restraints:
Allergy-Related Risks with the Monoclonal Antibody-Based Products and Lack of Sales and Access of Monoclonal Antibody Based Products in Low and Middle-Income Countries

Opportunities:
Immense Growth in High-Income Countries and Growing Number of Non-Communicable and Infectious Diseases

Market Leaders and their expansionary development strategies
On 5th November 2020, Merck entered into the agreement of the acquisition of VelosBio. The acquisition strengthens Merck’s Oncology Pipeline with VLS-101, an Investigational Antibody-Drug Conjugate to Treat Hematological Malignancies and Solid Tumors.
In September 2023, The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens. Manaolana Oncology seeks to build upon the innovative antibody production capabilities and intellectual property of MD Anderson to research and develop novel monoclonal antibodies
As per the WHO’s guidelines, monoclonal antibody-based products should be licensed. Requirement for description for structural elements such as active sites, receptors, ligand binding sites, and features for signal transduction.

Key Target Audience
Monoclonal Antibody Based Products Manufacturers, Regulatory Bodies, New Entrants, Potential Investors, Research and Development Institutes and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Murine
  • Chimeric
  • Humanized
  • Human
By Application
  • Therapeutics
  • Diagnostics
By Diseases Type
  • Non-communicable Diseases
  • Infectious Diseases

By End-User
  • Pharmaceutical Companies
  • Global Health Agencies
  • Public Sector Entities
  • Philanthropic Organisations
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasingly Large Proportion of Pharmaceutical Company Pipelines
      • 3.2.2. Rising Awareness about Monoclonal Antibodies
    • 3.3. Market Challenges
      • 3.3.1. Limitations on the Monoclonal Antibody-Based Products
    • 3.4. Market Trends
      • 3.4.1. Raising Awareness of the Clinical, Public Health, and Economic Value
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Monoclonal Antibody Based Products, by Type, Application, Diseases Type, End-User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Monoclonal Antibody Based Products (Value)
      • 5.2.1. Global Monoclonal Antibody Based Products by: Type (Value)
        • 5.2.1.1. Murine
        • 5.2.1.2. Chimeric
        • 5.2.1.3. Humanized
        • 5.2.1.4. Human
      • 5.2.2. Global Monoclonal Antibody Based Products by: Application (Value)
        • 5.2.2.1. Therapeutics
        • 5.2.2.2. Diagnostics
      • 5.2.3. Global Monoclonal Antibody Based Products by: Diseases Type (Value)
        • 5.2.3.1. Non-communicable Diseases
        • 5.2.3.2. Infectious Diseases
      • 5.2.4. Global Monoclonal Antibody Based Products by: End-User (Value)
        • 5.2.4.1. Pharmaceutical Companies
        • 5.2.4.2. Global Health Agencies
        • 5.2.4.3. Public Sector Entities
        • 5.2.4.4. Philanthropic Organisations
        • 5.2.4.5. Others
      • 5.2.5. Global Monoclonal Antibody Based Products Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Monoclonal Antibody Based Products (Price)
      • 5.3.1. Global Monoclonal Antibody Based Products by: Type (Price)
  • 6. Monoclonal Antibody Based Products: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck Group (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Genentech/Roche (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. AbbVie (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Amgen/Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. MedImmune (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Zydus Lifesciences (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Serum Institute (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BD Biosciences (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amgen (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biotest (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Monoclonal Antibody Based Products Sale, by Type, Application, Diseases Type, End-User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Monoclonal Antibody Based Products (Value)
      • 7.2.1. Global Monoclonal Antibody Based Products by: Type (Value)
        • 7.2.1.1. Murine
        • 7.2.1.2. Chimeric
        • 7.2.1.3. Humanized
        • 7.2.1.4. Human
      • 7.2.2. Global Monoclonal Antibody Based Products by: Application (Value)
        • 7.2.2.1. Therapeutics
        • 7.2.2.2. Diagnostics
      • 7.2.3. Global Monoclonal Antibody Based Products by: Diseases Type (Value)
        • 7.2.3.1. Non-communicable Diseases
        • 7.2.3.2. Infectious Diseases
      • 7.2.4. Global Monoclonal Antibody Based Products by: End-User (Value)
        • 7.2.4.1. Pharmaceutical Companies
        • 7.2.4.2. Global Health Agencies
        • 7.2.4.3. Public Sector Entities
        • 7.2.4.4. Philanthropic Organisations
        • 7.2.4.5. Others
      • 7.2.5. Global Monoclonal Antibody Based Products Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Monoclonal Antibody Based Products (Price)
      • 7.3.1. Global Monoclonal Antibody Based Products by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Monoclonal Antibody Based Products: by Type(USD Million)
  • Table 2. Monoclonal Antibody Based Products Murine , by Region USD Million (2018-2023)
  • Table 3. Monoclonal Antibody Based Products Chimeric , by Region USD Million (2018-2023)
  • Table 4. Monoclonal Antibody Based Products Humanized , by Region USD Million (2018-2023)
  • Table 5. Monoclonal Antibody Based Products Human , by Region USD Million (2018-2023)
  • Table 6. Monoclonal Antibody Based Products: by Application(USD Million)
  • Table 7. Monoclonal Antibody Based Products Therapeutics , by Region USD Million (2018-2023)
  • Table 8. Monoclonal Antibody Based Products Diagnostics , by Region USD Million (2018-2023)
  • Table 9. Monoclonal Antibody Based Products: by Diseases Type(USD Million)
  • Table 10. Monoclonal Antibody Based Products Non-communicable Diseases , by Region USD Million (2018-2023)
  • Table 11. Monoclonal Antibody Based Products Infectious Diseases , by Region USD Million (2018-2023)
  • Table 12. Monoclonal Antibody Based Products: by End-User(USD Million)
  • Table 13. Monoclonal Antibody Based Products Pharmaceutical Companies , by Region USD Million (2018-2023)
  • Table 14. Monoclonal Antibody Based Products Global Health Agencies , by Region USD Million (2018-2023)
  • Table 15. Monoclonal Antibody Based Products Public Sector Entities , by Region USD Million (2018-2023)
  • Table 16. Monoclonal Antibody Based Products Philanthropic Organisations , by Region USD Million (2018-2023)
  • Table 17. Monoclonal Antibody Based Products Others , by Region USD Million (2018-2023)
  • Table 18. South America Monoclonal Antibody Based Products, by Country USD Million (2018-2023)
  • Table 19. South America Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 20. South America Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 21. South America Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 22. South America Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 23. Brazil Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 24. Brazil Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 25. Brazil Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 26. Brazil Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 27. Argentina Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 28. Argentina Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 29. Argentina Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 30. Argentina Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 31. Rest of South America Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 34. Rest of South America Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 35. Asia Pacific Monoclonal Antibody Based Products, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 39. Asia Pacific Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 40. China Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 41. China Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 42. China Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 43. China Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 44. Japan Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 45. Japan Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 46. Japan Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 47. Japan Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 48. India Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 49. India Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 50. India Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 51. India Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 52. South Korea Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 53. South Korea Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 54. South Korea Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 55. South Korea Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 56. Australia Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 57. Australia Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 58. Australia Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 59. Australia Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 64. Europe Monoclonal Antibody Based Products, by Country USD Million (2018-2023)
  • Table 65. Europe Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 66. Europe Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 67. Europe Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 68. Europe Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 69. Germany Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 70. Germany Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 71. Germany Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 72. Germany Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 73. France Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 74. France Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 75. France Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 76. France Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 77. Italy Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 78. Italy Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 79. Italy Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 80. Italy Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 81. United Kingdom Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 82. United Kingdom Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 83. United Kingdom Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 84. United Kingdom Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 85. Netherlands Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 86. Netherlands Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 87. Netherlands Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 88. Netherlands Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 89. Rest of Europe Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 90. Rest of Europe Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 91. Rest of Europe Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 92. Rest of Europe Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 93. MEA Monoclonal Antibody Based Products, by Country USD Million (2018-2023)
  • Table 94. MEA Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 95. MEA Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 96. MEA Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 97. MEA Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 98. Middle East Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 99. Middle East Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 100. Middle East Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 101. Middle East Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 102. Africa Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 103. Africa Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 104. Africa Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 105. Africa Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 106. North America Monoclonal Antibody Based Products, by Country USD Million (2018-2023)
  • Table 107. North America Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 108. North America Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 109. North America Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 110. North America Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 111. United States Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 112. United States Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 113. United States Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 114. United States Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 115. Canada Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 116. Canada Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 117. Canada Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 118. Canada Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 119. Mexico Monoclonal Antibody Based Products, by Type USD Million (2018-2023)
  • Table 120. Mexico Monoclonal Antibody Based Products, by Application USD Million (2018-2023)
  • Table 121. Mexico Monoclonal Antibody Based Products, by Diseases Type USD Million (2018-2023)
  • Table 122. Mexico Monoclonal Antibody Based Products, by End-User USD Million (2018-2023)
  • Table 123. Monoclonal Antibody Based Products: by Type(USD/Units)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Monoclonal Antibody Based Products: by Type(USD Million)
  • Table 135. Monoclonal Antibody Based Products Murine , by Region USD Million (2025-2030)
  • Table 136. Monoclonal Antibody Based Products Chimeric , by Region USD Million (2025-2030)
  • Table 137. Monoclonal Antibody Based Products Humanized , by Region USD Million (2025-2030)
  • Table 138. Monoclonal Antibody Based Products Human , by Region USD Million (2025-2030)
  • Table 139. Monoclonal Antibody Based Products: by Application(USD Million)
  • Table 140. Monoclonal Antibody Based Products Therapeutics , by Region USD Million (2025-2030)
  • Table 141. Monoclonal Antibody Based Products Diagnostics , by Region USD Million (2025-2030)
  • Table 142. Monoclonal Antibody Based Products: by Diseases Type(USD Million)
  • Table 143. Monoclonal Antibody Based Products Non-communicable Diseases , by Region USD Million (2025-2030)
  • Table 144. Monoclonal Antibody Based Products Infectious Diseases , by Region USD Million (2025-2030)
  • Table 145. Monoclonal Antibody Based Products: by End-User(USD Million)
  • Table 146. Monoclonal Antibody Based Products Pharmaceutical Companies , by Region USD Million (2025-2030)
  • Table 147. Monoclonal Antibody Based Products Global Health Agencies , by Region USD Million (2025-2030)
  • Table 148. Monoclonal Antibody Based Products Public Sector Entities , by Region USD Million (2025-2030)
  • Table 149. Monoclonal Antibody Based Products Philanthropic Organisations , by Region USD Million (2025-2030)
  • Table 150. Monoclonal Antibody Based Products Others , by Region USD Million (2025-2030)
  • Table 151. South America Monoclonal Antibody Based Products, by Country USD Million (2025-2030)
  • Table 152. South America Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 153. South America Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 154. South America Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 155. South America Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 156. Brazil Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 157. Brazil Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 158. Brazil Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 159. Brazil Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 160. Argentina Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 161. Argentina Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 162. Argentina Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 163. Argentina Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 164. Rest of South America Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 165. Rest of South America Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 166. Rest of South America Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 167. Rest of South America Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 168. Asia Pacific Monoclonal Antibody Based Products, by Country USD Million (2025-2030)
  • Table 169. Asia Pacific Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 170. Asia Pacific Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 171. Asia Pacific Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 172. Asia Pacific Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 173. China Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 174. China Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 175. China Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 176. China Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 177. Japan Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 178. Japan Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 179. Japan Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 180. Japan Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 181. India Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 182. India Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 183. India Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 184. India Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 185. South Korea Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 186. South Korea Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 187. South Korea Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 188. South Korea Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 189. Australia Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 190. Australia Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 191. Australia Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 192. Australia Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 197. Europe Monoclonal Antibody Based Products, by Country USD Million (2025-2030)
  • Table 198. Europe Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 199. Europe Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 200. Europe Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 201. Europe Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 202. Germany Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 203. Germany Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 204. Germany Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 205. Germany Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 206. France Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 207. France Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 208. France Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 209. France Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 210. Italy Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 211. Italy Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 212. Italy Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 213. Italy Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 214. United Kingdom Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 215. United Kingdom Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 216. United Kingdom Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 217. United Kingdom Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 218. Netherlands Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 219. Netherlands Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 220. Netherlands Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 221. Netherlands Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 222. Rest of Europe Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 223. Rest of Europe Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 224. Rest of Europe Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 225. Rest of Europe Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 226. MEA Monoclonal Antibody Based Products, by Country USD Million (2025-2030)
  • Table 227. MEA Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 228. MEA Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 229. MEA Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 230. MEA Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 231. Middle East Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 232. Middle East Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 233. Middle East Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 234. Middle East Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 235. Africa Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 236. Africa Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 237. Africa Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 238. Africa Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 239. North America Monoclonal Antibody Based Products, by Country USD Million (2025-2030)
  • Table 240. North America Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 241. North America Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 242. North America Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 243. North America Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 244. United States Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 245. United States Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 246. United States Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 247. United States Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 248. Canada Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 249. Canada Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 250. Canada Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 251. Canada Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 252. Mexico Monoclonal Antibody Based Products, by Type USD Million (2025-2030)
  • Table 253. Mexico Monoclonal Antibody Based Products, by Application USD Million (2025-2030)
  • Table 254. Mexico Monoclonal Antibody Based Products, by Diseases Type USD Million (2025-2030)
  • Table 255. Mexico Monoclonal Antibody Based Products, by End-User USD Million (2025-2030)
  • Table 256. Monoclonal Antibody Based Products: by Type(USD/Units)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Monoclonal Antibody Based Products: by Type USD Million (2018-2023)
  • Figure 5. Global Monoclonal Antibody Based Products: by Application USD Million (2018-2023)
  • Figure 6. Global Monoclonal Antibody Based Products: by Diseases Type USD Million (2018-2023)
  • Figure 7. Global Monoclonal Antibody Based Products: by End-User USD Million (2018-2023)
  • Figure 8. South America Monoclonal Antibody Based Products Share (%), by Country
  • Figure 9. Asia Pacific Monoclonal Antibody Based Products Share (%), by Country
  • Figure 10. Europe Monoclonal Antibody Based Products Share (%), by Country
  • Figure 11. MEA Monoclonal Antibody Based Products Share (%), by Country
  • Figure 12. North America Monoclonal Antibody Based Products Share (%), by Country
  • Figure 13. Global Monoclonal Antibody Based Products: by Type USD/Units (2018-2023)
  • Figure 14. Global Monoclonal Antibody Based Products share by Players 2023 (%)
  • Figure 15. Global Monoclonal Antibody Based Products share by Players (Top 3) 2023(%)
  • Figure 16. Global Monoclonal Antibody Based Products share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Merck Group (Germany) Revenue: by Geography 2023
  • Figure 20. Genentech/Roche (United States) Revenue, Net Income and Gross profit
  • Figure 21. Genentech/Roche (United States) Revenue: by Geography 2023
  • Figure 22. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 23. AbbVie (United States) Revenue: by Geography 2023
  • Figure 24. Amgen/Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Amgen/Pfizer (United States) Revenue: by Geography 2023
  • Figure 26. MedImmune (United States) Revenue, Net Income and Gross profit
  • Figure 27. MedImmune (United States) Revenue: by Geography 2023
  • Figure 28. Zydus Lifesciences (India) Revenue, Net Income and Gross profit
  • Figure 29. Zydus Lifesciences (India) Revenue: by Geography 2023
  • Figure 30. Serum Institute (India) Revenue, Net Income and Gross profit
  • Figure 31. Serum Institute (India) Revenue: by Geography 2023
  • Figure 32. BD Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 33. BD Biosciences (United States) Revenue: by Geography 2023
  • Figure 34. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 35. Amgen (United States) Revenue: by Geography 2023
  • Figure 36. Biotest (Germany) Revenue, Net Income and Gross profit
  • Figure 37. Biotest (Germany) Revenue: by Geography 2023
  • Figure 38. Global Monoclonal Antibody Based Products: by Type USD Million (2025-2030)
  • Figure 39. Global Monoclonal Antibody Based Products: by Application USD Million (2025-2030)
  • Figure 40. Global Monoclonal Antibody Based Products: by Diseases Type USD Million (2025-2030)
  • Figure 41. Global Monoclonal Antibody Based Products: by End-User USD Million (2025-2030)
  • Figure 42. South America Monoclonal Antibody Based Products Share (%), by Country
  • Figure 43. Asia Pacific Monoclonal Antibody Based Products Share (%), by Country
  • Figure 44. Europe Monoclonal Antibody Based Products Share (%), by Country
  • Figure 45. MEA Monoclonal Antibody Based Products Share (%), by Country
  • Figure 46. North America Monoclonal Antibody Based Products Share (%), by Country
  • Figure 47. Global Monoclonal Antibody Based Products: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Merck Group (Germany)
  • Genentech/Roche (United States)
  • AbbVie (United States)
  • Amgen/Pfizer (United States)
  • MedImmune (United States)
  • Zydus Lifesciences (India)
  • Serum Institute (India)
  • BD Biosciences (United States)
  • Amgen (United States)
  • Biotest (Germany)
Additional players considered in the study are as follows:
Dendreon (United States) , Biogen (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 237 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Monoclonal Antibody Based Products Quantitative research analysis
Global Monoclonal Antibody Based Products Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Merck Group (Germany), Genentech/Roche (United States), AbbVie (United States), Amgen/Pfizer (United States), MedImmune (United States), Zydus Lifesciences (India), Serum Institute (India), BD Biosciences (United States), Amgen (United States) and Biotest (Germany) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Raising Awareness of the Clinical, Public Health, and Economic Value" is seen as one of major influencing trends for Monoclonal Antibody Based Products Market during projected period 2023-2030.
The Monoclonal Antibody Based Products market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Monoclonal Antibody Based Products Report?

Have a Query? Click Here

Other Related Reports

Disposable Cuvettes Comprehensive Study by Type (Polystyrene, Methacrylate), Capacity (Below 10 ml, 10-20 ml, Above 20 ml), End Use (Chemical, Healthcare & Medical, Food Sector, Environmental Protect...
$ 3450
Neuromodulation Devices Comprehensive Study by Type (Internal Neuromodulation, External Neuromodulation), Application (Depression, Parkinsons Disease, Tremor, Others), End Users (Hospitals, Clinics, ...
$ 3450
Orthobiologics Comprehensive Study by Type (Viscosupplementation Products, DBM, Synthetic Orthobiologics, BMP, Allografts, PRP, BMAC), Application (Fracture Recovery, Spinal Fusion, Soft Tissue Injur...
$ 3450
Maca Extract Comprehensive Study by Type (Raw, Gelatinized), Application (Health Drugs, Healthy Foods, Nutritional Supplements, Others), Uses (Leukemia, Chronic Fatigue Syndrome (CFS), Improving Ener...
$ 3750
Medical Tubing Comprehensive Study by Type (Polyvinyl Chloride (PVC), Thermoplastic Elastomer (TPE), Thermoplastic Polyurethane (TPU), Polyolefin, Silicone, Others), Application (Catheters & Cannulas...
$ 3750
Post-harvest Treatment Comprehensive Study by Type (Coatings, Fungicides, Cleaners, Sanitizers, Others), Treatment (Physical treatments (Heat treatment, Irradiation), Chemical treatments (Nitric oxid...
$ 3500